Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Catalent to Support Galapagos' Decentralized CAR-T Therapy Trials | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Catalent to Support Galapagos’ Decentralized CAR-T Therapy Trials

Will further expand Galapagos’ manufacturing network in the U.S. for improved patient experience.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Catalent Inc., the global CDMO recently acquired by Novo Holdings, has entered a strategic collaboration with Galapagos NV, a biotechnology company with operations in the U.S. and Europe, to support decentralized manufacturing for clinical studies of GLPG5101, Galapagos’ investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma (NHL) indications.

Catalent’s commercial cell therapy manufacturing facility in Princeton, New Jersey, will support manufacturing for Galapagos’ upcoming trials in New Jersey, New York, and surrounding areas.

Galapagos offers a decentralized manufacturing platform for cell therapies, which is intended to be set up near cancer treatment centers. This type of therapy has demonstrated significant effectiveness in patients with NHL, including those who have not responded to previous treatments. By positioning the manufacturing closer to patients, Galapagos’ platform aims to provide fresh, suitable, stem-like early memory cell therapy with a median vein-to-vein time of seven days. This approach eliminates the need for cryopreservation and bridging therapy.

“Catalent is passionate about increasing patient access to life-changing cell therapies like those being developed by Galapagos,” said Delara Motlagh, Vice President, Global Cell Therapy and Plasmid DNA at Catalent. “We are delighted by this collaboration to support Galapagos’ decentralized cell therapy approach to bring these pioneering treatments to more patients with certain aggressive forms of NHL in a median vein-to-vein time of seven days. With our highly experienced cell therapy team, state-of-the-art facility network, and central location, we enable timely delivery of these important therapies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics